Clinical Trial Goal
To find out if etavopivat is safe and works well to treat beta thalassemia or SCD in children and adults
You may be able to join this trial if you:
- Have beta thalassemia or SCD
- Have been treated with etavopivat
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Etavopivat is an erythrocyte pyruvate kinase (PKR) activator in red blood cells that doctors think can make your red blood cells heathier and lower the number of red blood cell transfusions needed.
You’ll get:
You’ll get:
- Etavopivat – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has not yet approved etavopivat.
Locations
Sponsors
lead: Novo Nordisk A/S
